Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02446821 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception
A Phase 2 study, sponsored by Sebela Women's Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 286
- Enrollment target
NCT02446821: Completed Phase 2 study, sponsored by Sebela Women's Health.
NCT02446821 is a Phase 2 study that has completed, run by Sebela Women's Health. The registered enrollment target is 286 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02446821, a Phase 2 study, has completed, sponsored by Sebela Women's Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 286 participants
- Enrollment target
Study Summary
Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
Primary Outcome
The Pearl Index is calculated as the number of on-treatment pregnancies per 100 woman-years of exposure. On-treatment pregnancy is defined as the estimated conception date being on or after the insertion date (must be a successful insertion) and no more than 7 days after the study drug is removed or expelled. One women year is defined as comprising thirteen 28-day cycles. A lower Pearl Index indicates greater contraceptive effectiveness.
Interventions
- DRUG VeraCept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 286 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-03-22 |
| Phase | Phase 2 |
What the finished NCT02446821 record still lists
NCT02446821 is an interventional study that assigns participants to a tested intervention. The registered 286 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (115% higher).
The record links to 0 conditions, and to 1 intervention - of which VeraCept is the first listed.
NCT02446821 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02446821 about?
NCT02446821 is a clinical study titled "Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception". Prospective, multi-center, single-arm, open-label, Phase II clinical study to evaluate the effectiveness, device placement, safety, and tolerability of VeraCept to support commencing a Phase III Clinical Study
What is the current status of trial NCT02446821?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 286 participants. The study started on 2015-06. Estimated completion is 2019-03-22.
What interventions are being tested in trial NCT02446821?
The interventions under investigation include: VeraCept (DRUG).
Who is sponsoring clinical trial NCT02446821?
This trial is sponsored by Sebela Women's Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02446821's enrollment target sits among peer trials
286 191st of 2000 higher than 1,809 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04781140 · 286 participants · Phase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
- NCT04936529 · 286 participants · Phase 2
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- NCT05183646 · 286 participants · Phase 3
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
- NCT05506878 · 286 participants · NA
Auriculo-Nerve Stimulation on Post-Operative Opioid Requirement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia